The STAT5 Inhibitor Pimozide Displays Efficacy in Models of Acute Myelogenous Leukemia Driven by FLT3 Mutations
Genes & Cancer · 01.07.2012 · 3 (7-8) · 503-511
DOI: 10.1177/1947601912466555 ↗Kurz gefasst
Fachartikel in der Zeitschrift Genes & Cancer, online erschienen am 19.11.2012. Verfasst von Erik A Nelson und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Dana-Farber Cancer Institute and Department of Medicine, Brigham and Women's Hospital, Boston, MA,USA. Die Arbeit wurde bisher 106-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS.
Abstract (Originalsprache)
Activation of the transcription factor STAT5 is essential for the pathogenesis of acute myelogenous leukemia (AML) containing the FLT3 internal tandem duplication (ITD) mutation. FLT3 ITD is a constitutively active tyrosine kinase that drives the activation of STAT5, leading to the growth and survival of AML cells. Although there has been some success in identifying tyrosine kinase inhibitors that block the function of FLT3 ITD, there remains a continued need for effective treatment of this disease. We have identified the psychotropic drug pimozide as an effective inhibitor of STAT5 function. Pimozide inhibits the tyrosine phosphorylation of STAT5, leading to the death of AML cells through the induction of apoptosis. Pimozide shows a combinatorial effect with the tyrosine kinase inhibitors midostaurin (PKC412) and sunitinib in the inhibition of STAT5 tyrosine phosphorylation and the induction of apoptosis. Significantly, pimozide reduces the tumor burden in a mouse model of FLT3-driven AML. Therefore, identifying STAT5 inhibitors may provide a new avenue for the treatment of AML, and these may be effective alone or in combination with tyrosine kinase inhibitors.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medical Oncology, Dana-Farber Cancer Institute and Department of Medicine, Brigham and Women's Hospital, Boston, MA,USA.
Förderung
- NIGMS NIH HHS
Zitieren
APA
Nelson, E. A., Walker, S. R., Xiang, M., Weisberg, E., Bar-Natan, M., Barrett, R., Liu, S., Kharbanda, S., Christie, A. L., Nicolais, M., Griffin, J. D., Stone, R. M., Kung, A. L., & Frank, D. A. (2012). The STAT5 Inhibitor Pimozide Displays Efficacy in Models of Acute Myelogenous Leukemia Driven by FLT3 Mutations. Genes & Cancer, 3(7-8), 503-511. https://doi.org/10.1177/1947601912466555
Vancouver
Nelson EA, Walker SR, Xiang M, Weisberg E, Bar-Natan M, Barrett R, et al. The STAT5 Inhibitor Pimozide Displays Efficacy in Models of Acute Myelogenous Leukemia Driven by FLT3 Mutations. Genes & Cancer. 2012;3(7-8):503-511. doi:10.1177/1947601912466555
BibTeX
@article{Nelson2012,
author = {Nelson, Erik A and Walker, Sarah R and Xiang, Michael and Weisberg, Ellen and Bar-Natan, Michal and Barrett, Rosemary and Liu, Suiyang and Kharbanda, Surender and Christie, Amanda L and Nicolais, Maria and Griffin, James D and Stone, Richard M and Kung, Andrew L and Frank, David A},
title = {The STAT5 Inhibitor Pimozide Displays Efficacy in Models of Acute Myelogenous Leukemia Driven by FLT3 Mutations},
journal = {Genes & Cancer},
year = {2012},
volume = {3},
number = {7-8},
pages = {503--511},
doi = {10.1177/1947601912466555}
}
EUVIMED